Company intelligence / Profile preview

PHAXIAM Therapeutics

Lyon, Auvergne-Rhône-Alpes, Francephaxiam.com ↗

Ownership: Public · PHXM
Employees: ~68
Development stage: Phase 2

Overview

PHAXIAM has developed a portfolio of phages targeting three major resistant pathogens responsible for most hospital-acquired infections. The company’s approach leverages the specificity and adaptability of bacteriophages to combat antibiotic resistance. As of early/mid–2025, no commercialized products; clinical results have shown promise but financial distress has halted further development.[1][6]

Therapeutic areas: Infectious Diseases
Modalities: Bacteriophage-based therapies ("phages")[1][7]Enzyme-based medicinal products[2][5]
Industry: Biotech

Drug pipeline

17 assets

eryaspase

16 more assets in the full pipeline.

Request access →

Partnerships

Partnership with Navarrabiomed to evaluate anti-S. aureus phages in new indications [from historical press releases via [7]]

Financials

Market cap: $19.9M
Total revenue: $0
Enterprise value: $20.3M

Beyond the preview

Go deeper on PHAXIAM Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PHAXIAM Therapeutics.

Explore the full profile